218 related articles for article (PubMed ID: 37528266)
1. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan.
Muhammad N; Azeem A; Bakar MA; Prajzendanc K; Loya A; Jakubowska A; Hamann U; Rashid MU
Breast Cancer Res Treat; 2023 Nov; 202(2):377-387. PubMed ID: 37528266
[TBL] [Abstract][Full Text] [Related]
2. Constitutional
Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
[TBL] [Abstract][Full Text] [Related]
3. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
[TBL] [Abstract][Full Text] [Related]
4. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan.
Rashid MU; Muhammad N; Shehzad U; Khan FA; Loya A; Hamann U
Fam Cancer; 2023 Jan; 22(1):31-41. PubMed ID: 35802266
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
[TBL] [Abstract][Full Text] [Related]
8. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Arif T; Anwar N
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
[TBL] [Abstract][Full Text] [Related]
9. Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development.
Nikolaienko O; Eikesdal HP; Ognedal E; Gilje B; Lundgren S; Blix ES; Espelid H; Geisler J; Geisler S; Janssen EAM; Yndestad S; Minsaas L; Leirvaag B; Lillestøl R; Knappskog S; Lønning PE
Genome Med; 2023 Dec; 15(1):104. PubMed ID: 38053165
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
11. Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement.
Schwartz M; Ibadioune S; Vacher S; Villy MC; Trabelsi-Grati O; Le Gall J; Caputo SM; Delhomelle H; Warcoin M; Moncoutier V; Bourneix C; Boutry-Kryza N; De Pauw A; Stern MH; Buecher B; Mouret-Fourme E; Colas C; Stoppa-Lyonnet D; Masliah-Planchon J; Golmard L; Bieche I
Breast; 2024 Feb; 73():103620. PubMed ID: 38096711
[TBL] [Abstract][Full Text] [Related]
12. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
14. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.
Wong EM; Southey MC; Fox SB; Brown MA; Dowty JG; Jenkins MA; Giles GG; Hopper JL; Dobrovic A
Cancer Prev Res (Phila); 2011 Jan; 4(1):23-33. PubMed ID: 20978112
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
16. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
Lobanova OE; Rossokha ZI; Medvedieva NL; Cheshuk VE; Vereshchako RI; Vershyhora VO; Fishchuk LY; Zakhartseva LM; Gorovenko NG
Exp Oncol; 2021 Mar; 43(1):56-60. PubMed ID: 33785722
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
20. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]